within Pharmacolibrary.Drugs.ATC.P;

model P01BF01_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.13,
    Cl             = 0.00058,
    adminDuration  = 600,
    adminMass      = 480 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1.17,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0020166666666666666,
    Tlag           = 30.0,            
    Vdp             = 0.0897,
    k12             = 9.6,
    k21             = 9.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01BF01_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Artemether and lumefantrine combination is an artemisinin-based antimalarial therapy (ACT) used for the treatment of uncomplicated Plasmodium falciparum malaria. It is a widely approved first-line treatment in many countries and is currently recommended by the World Health Organization for malaria therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers (non-pregnant, mixed sex, age ~18-45 years) after oral administration of standard dose for lumefantrine component.</p><h4>References</h4><ol><li><p>White, NJ, et al., &amp; Ezzet, F (1999). Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. <i>Clinical pharmacokinetics</i> 37(2) 105–125. DOI:<a href=\"https://doi.org/10.2165/00003088-199937020-00002\">10.2165/00003088-199937020-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10496300/\">https://pubmed.ncbi.nlm.nih.gov/10496300</a></p></li><li><p>Lohy Das, J, et al., &amp; Dorlo, TPC (2018). Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria. <i>Antimicrobial agents and chemotherapy</i> 62(10) –. DOI:<a href=\"https://doi.org/10.1128/AAC.00518-18\">10.1128/AAC.00518-18</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30061282/\">https://pubmed.ncbi.nlm.nih.gov/30061282</a></p></li><li><p>Wernsdorfer, WH (2004). Coartemether (artemether and lumefantrine): an oral antimalarial drug. <i>Expert review of anti-infective therapy</i> 2(2) 181–196. DOI:<a href=\"https://doi.org/10.1586/14787210.2.2.181\">10.1586/14787210.2.2.181</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15482185/\">https://pubmed.ncbi.nlm.nih.gov/15482185</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01BF01_1;
